Department of Emergency and Critical Care Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
J Surg Res. 2013 Oct;184(2):880-7. doi: 10.1016/j.jss.2013.03.099. Epub 2013 Apr 25.
To evaluate the effectiveness and safety of tranexamic acid (TEA) treatment in reducing perioperative blood loss and transfusion for patients receiving primary unilateral total knee arthroplasty (TKA) and to explore the most effective and safe protocol.
This study was based on Cochrane methodology for conducting meta-analyses. Only randomized controlled trials were eligible for this study. The participants were adults who had undergone primary unilateral TKA. The Review Manager Database (RevMan version 5.0, The Cochrane Collaboration, 2008) was used to analyze selected studies.
Nineteen randomized controlled trials involving 1114 patients were included. The use of TEA reduced postoperative drainage by a mean of 290 mL (95% confidence interval [CI] -385 to -196], total blood loss by a mean of 570 mL (95% CI -663 to -478), the number of blood transfusions per patient by 0.96 units (95% CI -1.32 to -0.59), and the volumes of blood transfusions per patient -440 mL (95% CI -518 to -362). TEA led to a significant reduction in the proportion of patients requiring blood transfusion (relative risk 0.39). There were no significant differences in venous thromboembolism or other adverse events among the study groups.
Intravenous TEA could significantly reduce perioperative blood loss and blood transfusion requirements following primary unilateral TKA. Its application is not associated with increased risk of venous thromboembolisms or other adverse events.
评估氨甲环酸(TEA)治疗在减少初次单侧全膝关节置换术(TKA)患者围手术期失血和输血方面的有效性和安全性,并探索最有效和安全的方案。
本研究基于 Cochrane 方法进行荟萃分析。仅符合条件的随机对照试验纳入本研究。参与者为接受初次单侧 TKA 的成年人。使用 Review Manager 数据库(RevMan 版本 5.0,Cochrane 协作组织,2008 年)分析入选研究。
纳入 19 项随机对照试验,共 1114 例患者。使用 TEA 可使术后引流量平均减少 290 mL(95%置信区间 [CI] -385 至 -196),总失血量平均减少 570 mL(95% CI -663 至 -478),每名患者输血次数减少 0.96 单位(95% CI -1.32 至 -0.59),每名患者输血量减少 440 mL(95% CI -518 至 -362)。TEA 可显著降低需要输血的患者比例(相对风险 0.39)。各组之间静脉血栓栓塞或其他不良事件发生率无显著差异。
静脉内给予 TEA 可显著减少初次单侧 TKA 后的围手术期失血和输血需求。其应用与静脉血栓栓塞或其他不良事件风险增加无关。